Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer

Hoon, Siao Nge; Lau, Peter K. H.; White, Alison M.; Bulsara, Max; Banks, Patricia; Redfern, Andrew

doi:10.1002/14651858.cd011220.pub2

Cited by 12 publications

(6 citation statements)

References 265 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed that the difference in PFS between CAP and TAX treatment is consistent with the results published by the Cochrane Breast Cancer Group that showed CAP to have a slight PFS advantage over TAX in HR+ mBC. 19 The lack of difference in OS between CAP and taxane treatment is also consistent with results from other studies. 15 , 20 …”

Section: Discussionsupporting

confidence: 90%

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

Mouabbi,

Qaio,

Shen

et al. 2023

The Oncologist

View full text Add to dashboard Cite

Background Hormone receptor (HR)-positive, HER2-negative metastatic invasive lobular breast cancer (mILC) is distinct from invasive ductal cancer (IDC) in clinicopathologic and molecular characteristics, impacting its response to systemic therapy. While endocrine therapy (ET) combined with targeted therapies has shown efficacy in ET-sensitive mILC, data on chemotherapy in ET-refractory mILC remain limited. We investigated the efficacy of single-agent capecitabine (CAP) versus taxanes (TAX) in ET-refractory HR+ HER2-negative patients with mILC. Materials and Methods Using data from the MD Anderson prospectively collected breast cancer database, we identified patients with HR+ HER2-negative mILC who received prior ET and first-time chemotherapy in the metastatic setting. We compared outcomes between 173 CAP-treated and 96 TAX-treated patients. Results CAP-treated patients had significantly better median progression-free survival (PFS) than TAX-treated patients (8.8 vs 5.0 months, HR 0.63, P < .001). Overall survival (OS) did not differ significantly between the groups (42.7 vs 36.6 months for CAP vs TAX, respectively, HR 0.84, P = .241). Multivariate analyses for PFS and OS revealed better outcomes in subjects with fewer metastatic sites and those exposed to more lines of ET. Additionally, Black patients showed worse OS outcomes compared to White patients (HR 2.46; P = .001). Conclusion In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.

show abstract

Section: Discussionsupporting

confidence: 90%

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

Mouabbi,

Qaio,

Shen

et al. 2023

The Oncologist

View full text Add to dashboard Cite

show abstract

“…There was no significant improvement in OS in patients treated with capecitabine alone (HR = 1.19, 95% CI: 0.98–1.45). 25 …”

Section: Resultsmentioning

confidence: 99%

Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses

Yin¹,

Zhu²,

Wang³

et al. 2022

IJGM

View full text Add to dashboard Cite

Purpose In recent years, many meta-analyses of triple-negative breast cancer (TNBC) treatment have been published; however, these studies still lack systematic summary. Therefore, the aim of this study is to summarize and evaluate the evidence level and efficacy of treatment for TNBC. Materials and Methods Retrospective and prospective studies on treatment of TNBC were searched in the PubMed, Embase, and Cochrane Library databases. The literature search deadline was June 30, 2021. Two investigators independently screened the literature and extracted the data. In addition, the joint World Health Organization–United Nations Food and Agriculture Organization expert consultation was used to evaluate the validity of the evidence. Results A total of 28 meta-analyses were included in this study. The treatment interventions for TNBC mainly included surgery, chemotherapy (CT), radiotherapy, molecular targeted therapy, immunotherapy, zoledronic acid, and gonadotropin-releasing hormone (GnRH) analog. Platinum improves the pathological complete response (PCR) rate of patients treated with neoadjuvant chemotherapy (NACT), the objective remission rate (ORR) and overall survival (OS) in patients with metastatic triple-negative breast cancer. Capecitabine improves disease-free survival (DFS) and OS in patients treated with adjuvant CT. Bevacizumab was added to NACT to improve the PCR rate in patients. Immunotherapy improves the PCR rate in patients treated with NACT. The improvement in PCR rate in patients with high Ki67 expression treated with neoadjuvant therapy is highly suggestive. Other interventions had suggestive or weak evidence. Conclusion Among the strategies for treating TNBC, platinum, bevacizumab, and immunotherapy can lead to better PCR rates as part of a NACT regimen. Capecitabine as adjuvant CT and platinum in the treatment of metastatic TNBC can benefit patients’ survival. However, the effectiveness of other interventions for TNBC is not yet clear. Further research is needed in the future to obtain more reliable clinical evidence.

show abstract

“…In the study assessing efficacy of adjuvant capecitabine for BC after preoperative chemotherapy, the most common adverse effect was the hand-foot syndrome [45]. In the next study, Hoon et al evaluated use of chemotherapy regimens containing capecitabine compared with regimens not containing capecitabine on receptorpositive and hormone receptor-negative BC cases [46]. Addition of capecitabine as neoadjuvant and adjuvant therapy resulted in higher frequency of diarrhea and hand-foot syndrome.…”

Section: Chemotherapymentioning

confidence: 99%

“…In addition, 3 or 4 grade febrile neutropenia was less common in capecitabine arms in adjuvant studies, while there were no differences in neoadjuvant settings. Hand-foot syndrome manifests in redness, tightness of the skin, palmoplantar numbness, pain in the soles and palms [46,47]. Moreover, in recent studies hand-foot syndrome was noted as a predictor of prolonged progression-free survival (PFS) and overall survival (OS) in patients treated with bevacizumab plus capecitabine (BEV-CAP) for locally recurrent/metastatic BC (LR/mBC) [48].…”

Section: Chemotherapymentioning

confidence: 99%

Adverse effects in the management of breast cancer – recent studies

Maksymowicz,

Machowiec,

Korzeniowska

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose Breast cancer (BC) management includes local therapies surgery, radiotherapy and systemic – hormonotherapy, chemotherapy, targeted and immunotherapy. However, some adverse events of these treatment strategies limit their wide administration in BC therapy. The aim of the study was to present adverse effects in the management of BC, prevention and treatment of them. State of the knowledge Surgery of the breast leads to lymphedema, pain, and anatomical changes. The most characteristic adverse event of radiotherapy is radiation dermatitis which is more probable among obese, older patients, females, and smokers. Other side effects are pneumonia, cardiac and pulmonary injury. Chemotherapeutics lead to complications such as anthracyclines-induced cardiotoxicity. As a consequence of endocrine therapy, patients are affected by vasomotor, musculoskeletal, and vulvovaginal symptoms. Immune checkpoint inhibitors may cause immune-related adverse events (irAEs), which are usually mild. When severe irAEs occur, immunosuppressive drugs are used. Depending on stage, toxicities of the therapies can lead to interrupting the treatment of BC. Moreover, drug resistance is an important therapeutic obstacle in BC treatment. Conclusion The application of a diversity of drugs in the treatment of breast cancer is associated with adverse effects which limit its efficacy. It is vital to develop novel, targeted therapeutic methods to optimize outcomes of patients. Given the adverse effects of breast cancer therapies and drug resistance, it is vital to develop novel, targeted therapeutic methods.

show abstract

Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer

Cited by 12 publications

References 265 publications

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses

Adverse effects in the management of breast cancer – recent studies

Contact Info

Product

Resources

About